Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Visugromab and Nivolumab in Muscle Invasive Bladder Cancer
NCT06059547Phase 2Completed
- Sponsor
- CatalYm
- Start
- Sep 2023
- Primary completion
- Oct 2025
- Countries
- 1
01
Overview
A Phase 2 trial of visugromab in bladder cancer, sponsored by CatalYm. Started Sep 2023; status: completed.
02
Drugs
visugromab
03
Conditions
bladder cancer
Beyond the preview
Go deeper on NCT06059547.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06059547.